EUVIMEDEUVIMED entdecken
Crossref

Myeloablative haploidentical t‐cell replete hematopoietic cell transplantation with post‐transplant cyclophosphamide in high‐risk hematological malignancies: Bending the learning curve in a middle‐income setting

Sanket P. Shah, Vivek S. Radhakrishnan, Ganesh S. Jaishetwar, Reghu K. Sukumaran, Jeevan Kumar, Saurabh J. Bhave, Mita Roychowdhury, Sayak Chaudhuri, Deepak K. Mishra, Reena Nair, Shekhar Krishnan, Mammen Chandy

ADVANCES IN CELL AND GENE THERAPY · 2021

DOI: 10.1002/acg2.106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ADVANCES IN CELL AND GENE THERAPY, 2021. Verfasst von Sanket P. Shah und 11 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Shah, S. P., Radhakrishnan, V. S., Jaishetwar, G. S., Sukumaran, R. K., Kumar, J., Bhave, S. J., Roychowdhury, M., Chaudhuri, S., Mishra, D. K., Nair, R., Krishnan, S., & Chandy, M. (2021). Myeloablative haploidentical t‐cell replete hematopoietic cell transplantation with post‐transplant cyclophosphamide in high‐risk hematological malignancies: Bending the learning curve in a middle‐income setting. ADVANCES IN CELL AND GENE THERAPY. https://doi.org/10.1002/acg2.106

Vancouver

Shah SP, Radhakrishnan VS, Jaishetwar GS, Sukumaran RK, Kumar J, Bhave SJ, et al. Myeloablative haploidentical t‐cell replete hematopoietic cell transplantation with post‐transplant cyclophosphamide in high‐risk hematological malignancies: Bending the learning curve in a middle‐income setting. ADVANCES IN CELL AND GENE THERAPY. 2021. doi:10.1002/acg2.106

BibTeX
@article{Shah2021,
  author = {Shah, Sanket P. and Radhakrishnan, Vivek S. and Jaishetwar, Ganesh S. and Sukumaran, Reghu K. and Kumar, Jeevan and Bhave, Saurabh J. and Roychowdhury, Mita and Chaudhuri, Sayak and Mishra, Deepak K. and Nair, Reena and Krishnan, Shekhar and Chandy, Mammen},
  title = {Myeloablative haploidentical t‐cell replete hematopoietic cell transplantation with post‐transplant cyclophosphamide in high‐risk hematological malignancies: Bending the learning curve in a middle‐income setting},
  journal = {ADVANCES IN CELL AND GENE THERAPY},
  year = {2021},
  doi = {10.1002/acg2.106}
}
Kostenlos starten →